Show simple item record

dc.contributor.authorSchöffski, P
dc.contributor.authorWozniak, A
dc.contributor.authorLeahy, Michael G
dc.contributor.authorAamdal, S
dc.contributor.authorRutkowski, P
dc.contributor.authorBauer, S
dc.contributor.authorRichter, S
dc.contributor.authorGrünwald, V
dc.contributor.authorDebiec-Rychter, M
dc.contributor.authorSciot, R
dc.contributor.authorGeoerger, B
dc.contributor.authorMarréaud, S
dc.contributor.authorCollette, S
dc.contributor.authorNzokirantevye, A
dc.contributor.authorStrauss, S
dc.date.accessioned2018-04-29T21:04:33Z
dc.date.available2018-04-29T21:04:33Z
dc.date.issued2018-05
dc.identifier.citationThe tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. 2018, 94: 156-167 Eur J Canceren
dc.identifier.issn1879-0852
dc.identifier.pmid29567632
dc.identifier.doi10.1016/j.ejca.2018.02.011
dc.identifier.urihttp://hdl.handle.net/10541/620927
dc.description.abstractAlveolar rhabdomyosarcomas (ARMSs) can harbour MET and anaplastic lymphoma kinase (ALK) alterations. We prospectively assessed crizotinib in patients with advanced/metastatic ARMS.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer (Oxford, England : 1990)en
dc.titleThe tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.en
dc.typeArticleen
dc.contributor.departmentDepartment of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuvenen
dc.identifier.journalEuropean Journal of Canceren
refterms.dateFOA2020-05-01T14:37:02Z
html.description.abstractAlveolar rhabdomyosarcomas (ARMSs) can harbour MET and anaplastic lymphoma kinase (ALK) alterations. We prospectively assessed crizotinib in patients with advanced/metastatic ARMS.


Files in this item

Thumbnail
Name:
Strauss_90101 ARMS Manuscript_ ...
Size:
561.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record